NeoGenomics is First to Offer Molecular Testing for Resistance to Bruton ...
... therapies for the lymphoproliferative disorders. We have learned, in particular based on our experience with BCR-ABL1 inhibitors in chronic myeloid leukemia, that dynamic monitoring of response and resistance is critical to optimal use of targeted ...
MarketWatch - Thu, 23 Oct 2014 04:05

What Else Is Under the Hood for Catalyst Pharma?
A partial list includes non-SCLC; neuroendocrine carcinomas; lymphosarcoma; malignant thymoma; cancers of the breast, stomach, colon, prostate, bladder, kidney, gallbladder, and rectum; basal cell carcinoma; leukemia; lymphoproliferative disorders such ...
24/7 Wall St. - Tue, 30 Sep 2014 13:15



Inflammatory Bowel Disease Activated by Inhibitors of Apoptosis
Additionally, the researchers learned that XIAP may lead to IBD – the 2 X-linked disorders, X-linked immune disorder (XLP2) and X-linked lymphoproliferative disease (XLP1), both share recurring, potentially fatal bouts of hemophagocytic ...
HCPLive - Sat, 25 Oct 2014 03:13

Abstract and Introduction
Nonetheless, its role and clinical application still lack validation in autoimmune diseases, including rheumatic conditions. This is partly attributed to the significant gap in our understanding of its regulatory role and how either overexpression of ...
Medscape - Tue, 30 Sep 2014 21:18

Chimerix's (CMRX) CEO Michelle Berrey Hosts R&D Update (Transcript) (CMRX)
EBV for example is predominantly associated with lymphoproliferative disorder in these patients. CMV is associated with its own syndrome. The purpose of looking at those other viruses just simply to make the points of these patients typically aren't ...
Seeking Alpha (registration) - Wed, 15 Oct 2014 22:08


1  


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014